The North America CGM market is expected to grow at a CAGR of 18.91%, from an initial value of US$3,200.139 million in 2021 to US$10,759.223 million by 2028.
Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.
Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint all because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. As a result, the market for continuous glucose monitoring devices offers huge potential for producers of insulin pumps and glucose monitor patches. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.
In recent years, diabetes incidence had alarmingly increased in the North American continent. Diabetes rates are at an all-time high in industrialized nations like the United States and Canada, mostly because of lifestyle modifications. Many health issues are related to diabetes. Diabetes patients need to make several adjustments throughout the day to keep their blood glucose levels within normal ranges. For example, they may need to administer more insulin or consume more carbs. Hence, it is anticipated that the market would expand as more people with diabetes use continuous monitoring devices.
In North America, CGM sensors account for the largest market share.
For patients with recurrent hypoglycemia episodes, sensor-augmented pumps, and gestational diabetes who are on a continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) regimen of insulin, CGM sensors have shown to be very helpful. Published randomized controlled studies (RCTs) have demonstrated how CGM sensors can mitigate hypoglycemia episodes and lower glycemic fluctuation. The rising global incidence of diabetes mellitus, which increases the financial burden on individuals, governments, and clinical systems, has been a major concern in North America.
Demand for continuous glucose monitoring devices is projected to rise due to an increase in the prevalence of diabetes.
Many factors, such as increasing urbanization and the growing tendency towards a sedentary lifestyle in developing and industrialized countries, are the main causes of the increased incidence of diabetes. A key factor in the growing global acceptance of these monitoring devices has been the rise of Type-1 or insulin-dependent Type-2 diabetic patients. Also, a significant population with insulin-dependent diabetes, the introduction of new technologies by industry participants, and favorable reimbursement rules all contribute to an increase in demand for diabetes monitoring tools like CGMs. The above-mentioned strong factors have led to expectations that the market for continuous glucose monitoring devices would grow.
United States is projected to be the prominent market shareholder in the CGM Market in North America and is anticipated to continue throughout the forecast period.
In the North American region, a high CAGR is anticipated for the United States. The United States dominates the market, among other nations, because of its population's high prevalence of diabetes and its capacity to adapt to new technologies. Start-up businesses in the diabetes industry are innovating new technologies in the United States. Examples include Glooko, OneDrop, Truly, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, Orgenesis, etc. The usage of CGM devices in addition to insulin pumps is essential. It may be assumed that the number of CGM devices marketed will increase as more diabetic people use insulin pumps to regulate their blood sugar levels.
Market Key Developments
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Market Size Value in 2021 | US$3,200.139 million |
| Market Size Value in 2028 | US$10,759.223 million |
| Growth Rate | CAGR of 18.91% from 2021 to 2028 |
| Base Year | 2021 |
| Forecast Period | 2023 – 2028 |
| Forecast Unit (Value) | USD Million |
| Segments Covered | Application, End-User Industry, and Country |
| Regions Covered | United States, Canada, Mexico |
| Companies Covered | Dexcom Inc., Abbott Laboratories, Medtronic plc, Senseonics Holdings Inc., Tandem Diabetes Care Inc., Insulet Corporation, Ascensia Diabetes Care Holdings AG, Ypsomed AG, Roche Diabetes Care Inc., GlySens Incorporated |
| Customization Scope | Free report customization with purchase |
Segmentation: